NDAORALSOLUTION
Approved
May 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
KHINDIVI (hydrocortisone) by PharmaIN is corticosteroid hormone receptor agonists [moa]. Approved for adrenal insufficiency, congenital adrenal hyperplasia. First approved in 2025.
Drug data last refreshed 20h ago
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications (2)
Worked on KHINDIVI at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.